Announcement • Nov 18
Universal Biosensors, Inc. Files Form 15 Universal Biosensors, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.0001 per share. Reported Earnings • Aug 05
Second quarter 2025 earnings released: AU$0.022 loss per share (vs AU$0.014 loss in 2Q 2024) Second quarter 2025 results: AU$0.022 loss per share (further deteriorated from AU$0.014 loss in 2Q 2024). Revenue: AU$1.21m (down 26% from 2Q 2024). Net loss: AU$6.61m (loss widened 74% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings. Announcement • Jul 07
Universal Biosensors, Inc. Announces Resignation of Craig Coleman as Member of the Board of Directors On June 30, 2025, Craig Coleman resigned as a member of the Board of Directors (the “Board”) of Universal Biosensors, Inc. Mr. Coleman’s decision to resign from the Board was not the result of any dispute or disagreement with the Company, its management, its Board, or any committee of the Board on any matter relating to the Company’s operations, policies or practices. The Company and the Board extend their gratitude to Mr. Coleman for his contributions to the Company. In connection with Mr. Coleman’s resignation, the Board reduced the size of the Board from five members to four. The Board and Judith Smith mutually agreed that such director would be reclassified from Class I to Class II to maintain the number of directors in each class as nearly equal as possible. Following the reclassification, the composition of the Board is as follows: Class I (term expiring at the 2027 Annual Meeting of Stockholders): Peter Mullin; Class II (term expiring at the 2026 Annual Meeting of Stockholders): Judith Smith; and Class III (term expiring at the 2028 Annual Meeting of Stockholders): David Hoey and Graham McLean. New Risk • Jun 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$11m free cash flow). Earnings have declined by 15% per year over the past 5 years. Market cap is less than US$10m (AU$12.8m market cap, or US$8.29m). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (AU$6.4m revenue, or US$4.1m). Reported Earnings • May 13
First quarter 2025 earnings released: AU$0.013 loss per share (vs AU$0.016 loss in 1Q 2024) First quarter 2025 results: AU$0.013 loss per share. Revenue: AU$1.55m (up 5.8% from 1Q 2024). Net loss: AU$3.84m (loss widened 12% from 1Q 2024). New Risk • May 07
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$15.2m (US$9.85m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$13m free cash flow). Earnings have declined by 18% per year over the past 5 years. Market cap is less than US$10m (AU$15.2m market cap, or US$9.85m). Minor Risk Revenue is less than US$5m (AU$6.3m revenue, or US$4.1m). Announcement • Apr 04
Universal Biosensors, Inc., Annual General Meeting, May 12, 2025 Universal Biosensors, Inc., Annual General Meeting, May 12, 2025. Reported Earnings • Feb 27
Full year 2024 earnings released: AU$0.053 loss per share (vs AU$0.032 loss in FY 2023) Full year 2024 results: AU$0.053 loss per share (further deteriorated from AU$0.032 loss in FY 2023). Revenue: AU$6.28m (down 5.3% from FY 2023). Net loss: AU$14.2m (loss widened 111% from FY 2023). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings. Announcement • Feb 12
Universal Biosensors, Inc. Announces Company Secretary Changes Universal Biosensors, Inc. advised that in accordance with ASX Listing Rule 3.16.1, Mr. Peter Mullin, the company's Finance Director and Chief Financial Officer, has been appointed as Company Secretary of UBI, effective 12 February, 2025. For the purposes of ASX Listing Rule 12.6, Mr. Mullin will be the primary person responsible for communications with ASX in relation to Listing Rule matters. Mr. Salesh Balak has notified the Board of his resignation as Company Secretary, effective 12 February, 2025. Mr. Balak will retain the role of Corporate Advisor. New Risk • Jan 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 40% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$15m free cash flow). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Minor Risks Revenue is less than US$5m (AU$7.1m revenue, or US$4.4m). Market cap is less than US$100m (AU$28.9m market cap, or US$18.0m). Announcement • Dec 31
Universal Biosensors, Inc. Announces Chief Financial Officer Changes Universal Biosensors, Inc. announced the appointment of Mr. Peter Mullin to the role of Chief Financial Officer. Mr. Mullin brings to UBI deep experience from an outstanding career of executive leadership in diverse industries and roles as well as Board governance positions. He was most recently CEO of the Comfort Group and prior to that spent 15 years in senior leadership roles at ANZ Bank, including Managing Director for E*Trade. His experience also includes financial management roles at Orica, Yates and P&O. Current Chief Financial Officer Salesh Balak will assume the role of Company Secretary and Corporate Advisor. Salesh has served the Company for 17 years and acknowledge his dedication and expertise. New Risk • Nov 01
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$15m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$15m free cash flow). Earnings have declined by 19% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (40% increase in shares outstanding). Revenue is less than US$5m (AU$7.1m revenue, or US$4.6m). Market cap is less than US$100m (AU$37.3m market cap, or US$24.5m). Reported Earnings • Nov 01
Third quarter 2024 earnings released: AU$0.011 loss per share (vs AU$0.012 loss in 3Q 2023) Third quarter 2024 results: AU$0.011 loss per share. Revenue: AU$1.87m (down 2.5% from 3Q 2023). Net loss: AU$3.41m (loss widened 31% from 3Q 2023). Announcement • Aug 08
Universal Biosensors, Inc. to Report First Half, 2024 Results on Aug 09, 2024 Universal Biosensors, Inc. announced that they will report first half, 2024 results on Aug 09, 2024 Reported Earnings • Aug 03
Second quarter 2024 earnings released: AU$0.014 loss per share (vs AU$0.007 profit in 2Q 2023) Second quarter 2024 results: AU$0.014 loss per share (down from AU$0.007 profit in 2Q 2023). Revenue: AU$1.63m (up 25% from 2Q 2023). Net loss: AU$3.79m (down 371% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings. Recent Insider Transactions • May 05
Non-Executive Director recently bought AU$50k worth of stock On the 1st of May, Craig Coleman bought around 217k shares on-market at roughly AU$0.23 per share. This transaction amounted to 29% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought AU$84k more in shares than they have sold in the last 12 months. Reported Earnings • May 03
First quarter 2024 earnings released: AU$0.016 loss per share (vs AU$0.018 loss in 1Q 2023) First quarter 2024 results: AU$0.016 loss per share (improved from AU$0.018 loss in 1Q 2023). Revenue: AU$1.47m (up 13% from 1Q 2023). Net loss: AU$3.44m (loss narrowed 9.2% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings. Announcement • Apr 09
Universal Biosensors, Inc., Annual General Meeting, May 30, 2024 Universal Biosensors, Inc., Annual General Meeting, May 30, 2024, at 10:01 E. Australia Standard Time. Agenda: To consider and vote on the election of one member of the Board of Directors to hold office until the 2027 annual meeting of stockholders and until her successor is duly elected and qualify; to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the accompanying Proxy Statement; and to transact such other business as may properly come before the Meeting and any adjournment or postponement thereof. New Risk • Mar 29
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 59% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (8.5% increase in shares outstanding). Revenue is less than US$5m (AU$6.6m revenue, or US$4.3m). Market cap is less than US$100m (AU$46.1m market cap, or US$30.0m). Announcement • Mar 26
Universal Biosensors, Inc., Annual General Meeting, Apr 10, 2024 Universal Biosensors, Inc., Annual General Meeting, Apr 10, 2024, at 10:01 E. Australia Standard Time. Agenda: To consider pursuant to and in accordance with Listing Rule 10.11 of the Australian Securities Exchange and for all other purposes, approval is given for the Company to issue 13,849,567 options over fully paid ordinary shares (common stock) in the Company (“Underwriter Options”) to Viburnum Funds Pty Ltd, or its nominee, on the terms and conditions set out in the proxy statement accompanying this Notice; to pursuant to and in accordance with Listing Rule 7.4 of the Australian Securities Exchange and for all other purposes, the Company’s stockholders ratify the issue by the Company of 16,666,667 CHESS Depositary Interests over fully paid ordinary shares (common stock) in the Company (“Placement CDIs”) to certain institutional investors at an issue price of A$0.15 per Placement CDI on March 25, 2024, on the terms and conditions set out in the proxy statement accompanying this Notice; and to discuss other matters. New Risk • Mar 26
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 59% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (9.0% increase in shares outstanding). Revenue is less than US$5m (AU$6.6m revenue, or US$4.3m). Market cap is less than US$100m (AU$44.0m market cap, or US$28.8m). Recent Insider Transactions Derivative • Mar 26
Chief Executive Officer exercised options to buy AU$259k worth of stock. On the 25th of March, John Sharman exercised options to buy 1m shares at a strike price of around AU$0.31, costing a total of AU$417k. This transaction amounted to 383% of their direct individual holding at the time of the trade. Since June 2023, John has owned 356.22k shares directly. Company insiders have collectively bought AU$452k more than they sold, via options and on-market transactions, in the last 12 months. Announcement • Mar 26
Universal Biosensors, Inc. has completed a Follow-on Equity Offering in the amount of AUD 2.5 million. Universal Biosensors, Inc. has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.
Security Name: Chess Depositary Interests
Security Type: Depositary Receipt (Common Stock)
Securities Offered: 16,666,667
Price\Range: AUD 0.15
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Announcement • Mar 05
Universal Biosensors, Inc. to Report Fiscal Year 2023 Results on Mar 07, 2024 Universal Biosensors, Inc. announced that they will report fiscal year 2023 results at 10:00 AM, AUS Eastern Standard Time on Mar 07, 2024 Reported Earnings • Oct 31
Third quarter 2023 earnings released: AU$0.012 loss per share (vs AU$0.024 loss in 3Q 2022) Third quarter 2023 results: AU$0.012 loss per share (improved from AU$0.024 loss in 3Q 2022). Revenue: AU$1.92m (up 182% from 3Q 2022). Net loss: AU$2.60m (loss narrowed 48% from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. New Risk • Aug 01
New minor risk - Financial position The company has less than a year of cash runway based on its current free cash flow. Free cash flow: -AU$17m This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 64% per year over the past 5 years. Minor Risks Less than 1 year of cash runway based on current free cash flow (-AU$17m). Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (AU$4.0m revenue, or US$2.7m). Market cap is less than US$100m (AU$51.0m market cap, or US$33.8m). Reported Earnings • Aug 01
Second quarter 2023 earnings released: EPS: AU$0.007 (vs AU$0.024 loss in 2Q 2022) Second quarter 2023 results: EPS: AU$0.007 (up from AU$0.024 loss in 2Q 2022). Revenue: AU$1.30m (down 4.2% from 2Q 2022). Net income: AU$1.40m (up AU$6.05m from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. New Risk • Jul 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 61% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (AU$4.1m revenue, or US$2.7m). Market cap is less than US$100m (AU$51.0m market cap, or US$33.9m). Reported Earnings • May 12
First quarter 2023 earnings released: AU$0.018 loss per share (vs AU$0.025 loss in 1Q 2022) First quarter 2023 results: AU$0.018 loss per share (improved from AU$0.025 loss in 1Q 2022). Revenue: AU$1.30m (down 25% from 1Q 2022). Net loss: AU$3.79m (loss narrowed 16% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Reported Earnings • Feb 25
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: AU$0.14 loss per share (further deteriorated from AU$0.059 loss in FY 2021). Revenue: AU$4.52m (down 22% from FY 2021). Net loss: AU$26.9m (loss widened 156% from FY 2021). Revenue missed analyst estimates by 22%. Earnings per share (EPS) also missed analyst estimates by 109%. Revenue is forecast to grow 59% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings. Announcement • Jan 30
Universal Biosensors, Inc. Launches New Product, Fructose Test for Sentia Universal Biosensors, Inc. announced that it has launched its Fructose biosensor test, which is the 4th test on the Sentia wine testing platform. At the same time UBI has relaunched its Glucose test, which is the partner test used with Fructose to measure Total Residual Sugar during the winemaking process. Glucose & Fructose are the main fermentable sugars found in wine. They are natural sugars produced in the vines and play a key role in the wine making process. The levels of Glucose & Fructose are important indicators of grape quality and represent the amount of sugar that is available to the yeast for conversion into ethanol. Glucose & Fructose are monitored at each stage of the wine making process with high glucose levels present during ripening and high fructose levels present in over ripe grapes. These sugars are more closely monitored during the fermentation process as yeast consumes these sugars and converts them into ethanol. The ability to monitor and measure both glucose and fructose concentrations in real timeat the barrel side will allow wine makers to more accurately determine an endpoint for fermentation. Announcement • Jan 24
Universal Biosensors, Inc. completes Xprecia Prime clinical trial in USA Universal Biosensors, Inc. announced that it has recruited it's last patient and completed enrolment for its 360-patient "Xprecia Prime" PT/INR blood coagulation clinical study. The clinical study protocol was discussed at a FDA Pre Submission meeting and patients were enrolled accros the prescribed PT/INR measuring ranges. The study was conducted at five Clinical Sites in the USA. The study is designed to provide clinical evidence as to the performance and safety of Xprecia Prime and will be used in UBI's 510K submission to the FDA, which is expected to be lodged during first quarter of 2023. Announcement • Jan 17
Universal Biosensors, Inc. Announces Chairman Changes Universal Biosensors, Inc. announced Mr. Graham McLean has been appointed Chairman of the Board at UBI. Graham was appointed to the board of UBI in March 2022 and replaces Mr. Craig Coleman who will remain on the board as a Non-Executive Director. Mr. McLean is an experienced senior executive and has been a leader in the medical technology industry in Australia, Asia and USA for more than 20 years. His most recent executive role was with Stryker Corporation as President Asia Pacific from 2017 to 2020 where he delivered significant sales growth. Over the last few years under Craig's Chairmanship, UBI have made significant changes to the way it conducts its business. UBI has upgraded the Senior Management Team led by the recruitment of John Sharman as CEO, clarified its business strategy, strengthened its capital settings and most importantly developed a pipeline of market leading products which all use UBI's proprietary biosensor intellectual property and manufacturing platform. As UBI's products are progressively released during 2023, the opportunity and focus shifts to sales and revenue. Given Graham's experience in the global distribution of medical technology, Craig and the Board believes this is the right time to transition to him taking up the Chair. Recent Insider Transactions • Nov 17
Non-Executive Chairman recently bought AU$54k worth of stock On the 16th of November, Craig Coleman bought around 150k shares on-market at roughly AU$0.36 per share. This transaction amounted to 30% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Craig has been a buyer over the last 12 months, purchasing a net total of AU$205k worth in shares. Price Target Changed • Nov 16
Price target increased to AU$1.15 Up from AU$0.94, the current price target is provided by 1 analyst. New target price is 389% above last closing price of AU$0.23. Stock is down 76% over the past year. The company is forecast to post a net loss per share of AU$0.042 next year compared to a net loss per share of AU$0.059 last year. Reported Earnings • Oct 28
Third quarter 2022 earnings released: AU$0.024 loss per share (vs AU$0.016 loss in 3Q 2021) Third quarter 2022 results: AU$0.024 loss per share (further deteriorated from AU$0.016 loss in 3Q 2021). Revenue: AU$680.0k (down 41% from 3Q 2021). Net loss: AU$5.03m (loss widened 75% from 3Q 2021). Revenue is forecast to grow 67% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has fallen by 40% per year but the company’s share price has increased by 12% per year, which means it is well ahead of earnings. Price Target Changed • Oct 18
Price target increased to AU$1.15 Up from AU$0.94, the current price target is an average from 2 analysts. New target price is 342% above last closing price of AU$0.26. Stock is down 65% over the past year. The company is forecast to post a net loss per share of AU$0.083 next year compared to a net loss per share of AU$0.059 last year. Recent Insider Transactions • Aug 19
Non-Executive Chairman recently bought AU$56k worth of stock On the 17th of August, Craig Coleman bought around 200k shares on-market at roughly AU$0.28 per share. This was the largest purchase by an insider in the last 3 months. Craig has been a buyer over the last 12 months, purchasing a net total of AU$126k worth in shares. Major Estimate Revision • Aug 17
Consensus revenue estimates fall by 19% The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from AU$9.45m to AU$7.70m. Forecast losses increased from -AU$0.06 to -AU$0.08 per share. Medical Equipment industry in Australia expected to see average net income decline 20% next year. Consensus price target down from AU$0.94 to AU$0.91. Share price fell 14% to AU$0.28 over the past week. Reported Earnings • Aug 11
Second quarter 2022 earnings released: AU$0.024 loss per share (vs AU$0.01 loss in 2Q 2021) Second quarter 2022 results: AU$0.024 loss per share (down from AU$0.01 loss in 2Q 2021). Revenue: AU$1.36m (down 26% from 2Q 2021). Net loss: AU$4.65m (loss widened 161% from 2Q 2021). Over the next year, revenue is forecast to grow 149%, compared to a 15% growth forecast for the industry in Australia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance. Major Estimate Revision • Jun 23
Consensus revenue estimates fall by 10% The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from AU$10.6m to AU$9.45m. Forecast losses increased from -AU$0.05 to -AU$0.06 per share. Medical Equipment industry in Australia expected to see average net income decline 22% next year. Consensus price target down from AU$1.10 to AU$0.94. Share price fell 12% to AU$0.32 over the past week. Announcement • May 25
Universal Biosensors, Inc. has completed a Follow-on Equity Offering in the amount of AUD 20.007467 million. Universal Biosensors, Inc. has completed a Follow-on Equity Offering in the amount of AUD 20.007467 million.
Security Name: CHESS Depositary Interests
Security Type: Depositary Receipt (Common Stock)
Securities Offered: 25,983,723
Price\Range: AUD 0.77
Discount Per Security: AUD 0.03465
Transaction Features: Rights Offering Reported Earnings • May 02
First quarter 2022 earnings released: AU$0.025 loss per share (vs AU$0.008 loss in 1Q 2021) First quarter 2022 results: AU$0.025 loss per share (down from AU$0.008 loss in 1Q 2021). Revenue: AU$1.72m (up 11% from 1Q 2021). Net loss: AU$4.53m (loss widened 217% from 1Q 2021). Over the next year, revenue is forecast to grow 114%, compared to a 17% growth forecast for the industry in Australia. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 142 percentage points per year, which is a significant difference in performance. Announcement • May 02
Universal Biosensors, Inc., Annual General Meeting, Jun 21, 2022 Universal Biosensors, Inc., Annual General Meeting, Jun 21, 2022, at 10:00 AUS Eastern Standard Time. Agenda: To consider and vote on the election of two members of the Board of Directors to hold office until the Meeting of stockholders in 2025 and until their respective successors are duly elected and qualify; to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the accompanying Proxy Statement and to transact such other business as may properly come before the Meeting and any adjournment or postponement thereof. Price Target Changed • Apr 27
Price target increased to AU$1.25 Up from AU$1.05, the current price target is an average from 2 analysts. New target price is 79% above last closing price of AU$0.70. The company is forecast to post a net loss per share of AU$0.051 next year compared to a net loss per share of AU$0.059 last year. Breakeven Date Change • Apr 27
Forecast to breakeven in 2024 The 2 analysts covering Universal Biosensors expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of AU$6.20m in 2024. Average annual earnings growth of 90% is required to achieve expected profit on schedule. Announcement • Apr 19
Universal Biosensors, Inc. Announces Interim Results from the Peter Mac Sponsored Tn Antigen Development Clinical Study Universal Biosensors, Inc. announced interim results from the Peter Mac sponsored Tn Antigen 1 Development Clinical Study. UBI is developing a handheld portable Tn Antigen cancer biosensor using a "finger prick" blood test to accurately measure changes to a cancer patient's tumor status (monitoring of remission and reoccurrence) delivering easier, cheaper, and more frequent tests. The Tn Antigen biosensor test could be used by oncologists and cancer patients in clinics, hospitals, GP clinics or at home. The results suggest that the Tn Antigen handheld biosensor is potentially more sensitive and more specific than the existing FDA approved Carcinoembryonic Antigen "CEA" biomarker used for monitoring colorectal cancer (sensitivity 55.2% and specificity 83.6%)[5]. Sales of the CEA biomarker are estimated in excess of $3 billion pa. For prostate cancer subjects, the results suggest that the Tn Antigen biosensor is potentially more sensitive and more specific than the existing FDA approved Prostate-specific antigen "PSA" biomarker used for monitoring prostate cancer (sensitivity 85.4% and specificity 30.3%). Sales of the PSA biomarker are estimated in excess of $3 billion pa. The Peter Mac study consisted of subjects (n=66) from 3 tumour streams: Colorectal (n=16), Prostate (n=44) and Breast (n=6) [identified by Peter Mac]. These subjects were supplemented with cancer-free control subjects (n=10) collected by Universal Biosensors. Initial testing of the Peter Mac retrospective subjects began on UBI's legacy 2 electrode test strip configuration. Throughout the development process UBI identified that the 2 electrode strip design was not capable of reliably measuring in the sub nano-molar ranges required for the new lubricin-based technology. A new 3 electrode strip 4 has been designed that allows robust detection of analytes using the lubricin platform. The Peter Mac study was performed on both configuration of test strips. Although the sample sizes are not statistically significant and patient samples are from pre-screened cohorts, these development clinical results give UBI confidence in the Tn Antigen product and that there is significant improvements to be achieved through continued development of the chemistry and 3 electrode strip. Due to the small sample size (n=6) of the Peter Mac breast cancer subjects the outcome was inconclusive with little differentiation between cancer and control subjects for the 2 electrode strips although improved differentiation on the 3 electrode strips was observed (data not shown). As a result of the Peter Mac Development Clinical Trial results, UBI is investing in a new manufacturing line for three electrode test strips. The new manufacturing line will require an engineering upgrade of legacy test strip manufacturing lines and work has begun. This is expected to take between 9 and 12 months to complete with an estimated cost approaching $2 million. Victorian Cancer Biobank and CIC bioGUNE sponsored study update: UBI expects results from the Victorian Cancer Biobank sponsored study (n=130) on the three-electrode test strip design made on one of the R&D manufacturing lines to be available during first half 2022. UBI will also be retesting clinical samples from the CIC bioGUNE study on the three-electrode test strip designand expects results to be available during first half 2022. Reported Earnings • Feb 25
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: AU$0.059 loss per share (down from AU$0.043 loss in FY 2020). Revenue: AU$5.78m (up 80% from FY 2020). Net loss: AU$10.5m (loss widened 38% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 171 percentage points per year, which is a significant difference in performance. Announcement • Jan 18
Universal Biosensors, Inc. Announces the Launch of the Sentia Malic Acid Test into the Global Wine Market Universal Biosensors, Inc. announced the launch of the Sentia Malic Acid Test into the global wine market. First delivery and sales of the Sentia Malic Acid Test is scheduled for late January 2022 into USA, Australia and New Zealand markets. Malic Acid is one of the most important, time consuming and difficult tests performed by winemakers and typically takes winemakers 30 minutes but can take up to several hours to complete. In many instances Malic Acid is sent to third party laboratories for testing and in this case, results are expensive and can take several days to be delivered. The Sentia Malic Acid Test will provide wine makers with accurate and timely measurement of the Malic Acid in their wine within 60 seconds of sample application and at a low cost by using the Sentia portable, handheld device. Malic Acid is one of the main acids found in the acidity of grapes. Its concentration decreases the more a grape ripens, and it is used in the wine industry to determine the ripeness and variety of grapes. Malic acid is the principal acid found in wine and the course of malolactic fermentation is monitored by tracking the falling level of L-Malic Acid, and the simultaneous increasing level of L-Lactic acid. Typically, a winemaker will track and test the levels of Malic Acid in each variety of wine many times during the secondary fermentation process. The number of Malic Acid tests performed globally is estimated at 15 million. Reported Earnings • Aug 09
Second quarter 2021 earnings released: AU$0.01 loss per share (vs AU$0.017 loss in 2Q 2020) The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: AU$1.84m (up 237% from 2Q 2020). Net loss: AU$1.78m (loss narrowed 42% from 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 137 percentage points per year, which is a significant difference in performance. Reported Earnings • May 02
First quarter 2021 earnings released: AU$0.008 loss per share (vs AU$0.008 loss in 1Q 2020) The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: AU$1.55m (up 200% from 1Q 2020). Net loss: AU$1.43m (loss narrowed 2.2% from 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 112 percentage points per year, which is a significant difference in performance. Executive Departure • Mar 18
Independent Non-Executive Director has left the company On the 17th of March, Marshall Heinberg's tenure as Independent Non-Executive Director ended after 11.2 years in the role. As of December 2020, Marshall personally held only 20.00k shares (AU$8.7k worth at the time). Marshall is the only executive to leave the company over the last 12 months. Announcement • Mar 17
Universal Biosensors, Inc. Announces Resignation of Marshall Heinberg as Director Universal Biosensors, Inc. announced that Mr. Marshall Heinberg has resigned from the Board of the Company, effective as 17 March 2021. Reported Earnings • Feb 25
Full year 2020 earnings released: AU$0.043 loss per share (vs AU$0.027 loss in FY 2019) Full year 2020 results: Net loss: AU$7.64m (loss widened 58% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Announcement • Jan 29
Universal Biosensors, Inc. Enters into Non-Exclusive Distribution Agreement with Enartis Inc Universal Biosensors, Inc. announced that it has entered into a non-exclusive Distribution Agreement with Enartis Inc. ("Enartis") for the distribution of its wine testing device "Sentia" in the USA. The Distribution Agreement has no fixed term and there are standard renewal and termination options available to both parties. Is New 90 Day High Low • Jan 07
New 90-day high: AU$0.54 The company is up 84% from its price of AU$0.29 on 09 October 2020. The Australian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is down 2.0% over the same period. Announcement • Nov 25
Universal Biosensors, Inc. Releases SENTIA Universal Biosensors, Inc. commissioned an independent comparison validation study to determine the performance of its new hand held wine analyser, called SENTIATM ("Sentia") at California State University (Fresno Campus). Dr. Stephan Sommer, Director of the Viticulture and Enology at the California State University (Fresno Campus) conducted a detailed analysis of Sentia on 200 wine samples using the Ripperand FOSS FT2 WineScanTM SO2 method as comparison. The objective of this study was to compare the results for free sulfur dioxide of the Sentia analyzer to the most common established methods in the USA. The goal was to test all wines with the methods in duplicate and predict method agreement as well as calculate statistical determinations. The wines were selected based on the following specifications: still white and red wines only (no rosé wines), residual sugar less than 30 g/L (no dessert wines) and expected Free SO2 levels between 3 and 50 mg/L. Is New 90 Day High Low • Nov 09
New 90-day high: AU$0.34 The company is up 35% from its price of AU$0.26 on 11 August 2020. The Australian market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 12% over the same period. Recent Insider Transactions • Nov 04
Independent Non-Executive Director recently bought AU$62k worth of stock On the 2nd of November, Judith Smith bought around 200k shares on-market at roughly AU$0.31 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Announcement • Oct 06
Universal Biosensors, Inc. Announces Appointment of Promedeus s.r.o. as Its New Distribution Partner in Czech Republic and Slovak Republic Universal Biosensors, Inc. announced the appointment of Promedeus s.r.o., as its new distribution partner in Czech Republic and Slovak Republic for Xprecia Stride products. The deal includes first year forecast sales from Promedeus of 30,000 Strips and 200 Xprecia Stride Analyzers. UBI has already received the first order for product which has recently been delivered. 